

Références – Nevanac

1. Société canadienne d'ophtalmologie, Canadian Ophthalmological Society Cataract Surgery Clinical Practice Guideline Expert Committee, , Guide de pratique clinique factuelle de la Société canadienne d'ophtalmologie pour la chirurgie de la cataracte de l'œil adulte Can J Ophthalmol, 2008 Oct; 43 Suppl 1:S7-57, Peut être consulté à l'adresse : <http://pubs,nrc-cnrc.gc.ca/cjo/cjo43/i08-133.pdf>
2. Bollinger KE, Langston RH, What can patients expect from cataract surgery? Cleve Clin J Med, 2008 Mar;75(3):193-6, 199-200, Peut être consulté à l'adresse : <http://www.ccjm.org/content/75/3/193.full.pdf+html>
3. Toward Optimized Practice, Guideline for Surgical & Non-Surgical Management of Cataract in the Otherwise Healthy Adult Eye; 2008 [date de la dernière révision], Peut être consulté à l'adresse : http://www.topalbertadoctors.org/PDF/complete%20set/Cataracts/cataract_guideline.pdf
4. DeCroos FC, Afshari NA, Perioperative antibiotics and anti-inflammatory agents in cataract surgery, Curr Opin Ophthalmol, 2008 Jan; 19(1):22-6,
5. European Medicines Agency, Scientific discussion (Nevanac); 2007, Peut être consulté à l'adresse : <http://www.emea.europa.eu/humandocs/PDFs/EPAR/nevanac/H-818-en6.pdf>
6. Lane SS, Modi SS, Lehmann RP, Holland EJ, Nepafenac ophthalmic suspension 0,1% for the prevention and treatment of ocular inflammation associated with cataract surgery, J Cataract Refract Surg, 2007 Jan; 33(1):53-8,
7. Maxwell WA, Reiser HJ, Stewart RH, Cavanagh HD, Walters TR, Sager DP, Meuse PA, Nepafenac dosing frequency for ocular pain and inflammation associated with cataract surgery, J Ocul Pharmacol Ther, 2008 Dec;24(6):593-9,
8. Duong HV, Westfield KC, Chalkley TH, Ketorolac tromethamine LS 0,4% versus nepafenac 0,1% in patients having cataract surgery, Prospective randomized double-masked clinical trial, J Cataract Refract Surg, 2007 Nov;33(11):1925-9,
9. Mathys KC, Cohen KL, Impact of nepafenac 0,1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema, Eye, 2009 Feb 20,
10. Wolf EJ, Braunstein A, Shih C, Braunstein RE, Incidence of visually significant pseudophakic macular edema after uneventful phacoemulsification in patients treated with nepafenac, J Cataract Refract Surg, 2007 Sep;33(9):1546-9,
11. McCulley JP, Ketorolac versus nepafenac in cataract surgery, J Cataract Refract Surg, 2008 Mar;34(3):345-6,
12. Guidelines & Protocols Advisory Committee, Cataract – Treatment of Adults; 2007 [date de la dernière révision]. Peut être consulté à l'adresse : <http://www.bcguidelines.ca/gpac/pdf/cataract.pdf>
13. Cataract in the adult eye, Preferred practice pattern, In: American Academy of Ophthalmology (AAO), San Francisco (CA): American Academy of Ophthalmology (AAO); 2006, Peut être consulté à l'adresse : <http://one,ao.org/asset,axd?id=821cecfb-85c5-400d-a65f-7a9a727bc163>
14. American Optometric Association, Care of the adult patient with cataract, 2nd ed, St, Louis (MO): American Optometric Association; 1996, 84 p, (Optometric clinical practice guideline; no, 16), Peut être consulté à l'adresse : <http://one,ao.org/asset,axd?id=821cecfb-85c5-400d-a65f-7a9a727bc163>

15. Lindstrom R, The pharmacologic and pathophysiologic rationale for using NSAIDs in ocular inflammatory disease and ocular surgery, *International Ophthalmology Clinics*, 2006;46(4):7-11,
16. Bartlett JD, Fiscella RG, Bennett E, Jaanus SD, Rowsey JJ, Zimmerman TJ, editors, *Ophthalmic Drug Facts*, 2001, St, Louis: Facts and Comparisons; 2001,
17. American Society of Health-System Pharmacists, AHFS Drug Information® (2009), In: STAT!Ref Online Electronic Medical Library [database on the Internet; cited March 13, 2009], Bethesda: American Society of Health-System Pharmacists; 2009,
18. Corticosteroids: Eye Ear Nose, e-CPS 2009,
19. George SP, Cataract Surgery Postoperative Care, *In: Gray J, ed, Therapeutic Choices, 5th edition*, Ottawa, ON: Association canadienne des pharmaciens, 2007: 273-84,